KURA ONCOLOGY, INC. Line of Credit Facility, Remaining Borrowing Capacity
KURA ONCOLOGY, INC. (KURA) had Line of Credit Facility, Remaining Borrowing Capacity of $12.50 million as of 2016-04-27, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity · last filed 2017-11-07
- 2016-04-27: Line of Credit Facility, Remaining Borrowing Capacity $12.50M.
| Period end | Line of Credit Facility, Remaining Borrowing Capacity |
|---|---|
| 2016-04-27 | $12.50M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |